Potential Role of Sirtuins As Epigenetic Biomarkers of the Patient with Atherosclerosis or Calcific Aortic Stenosis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: lncRNA signature analyses.
- Who it may be relevant to
- Registry conditions: Atherosclerosis and Calcific Aortic Stenosis with and Without Diabetes. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Italy
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Potential Role of Sirtuins As Epigenetic Biomarkers for the Clinical Management of the Patient with Atherosclerosis or Calcific Aortic Stenosis
Overview
The project aims to shed light on the role of Sirtuins, enzymes belonging to the third class of histone deacetylases (class III) involved in epigenetic modifications (deacetylation), focusing mainly on Sirtuin 6 (SIRT6), as a regulator of atherosclerosis and severe aortic valve stenosis through molecular-based and epigenetic studies in human VSMC cells.
Interventions
- Diagnostic test lncRNA signature analyses
Specific validation experiments will be performed by Real-Time PCR (C-reactive protein), Western Blot, flow cytometry and microscopy
Primary outcome measures
- To evaluate by analysis of data obtained from NGS techniques whether and which proteins belonging to the Sirtuin family may be deregulated in patients with atherosclerosis or calcific aortic stenosis [Time frame: 36 months]
Secondary outcome measures (1)
- To evaluate the experimental results achieved in the clinical-diagnostic context [Time frame: 36 months]
Eligibility criteria
Inclusion criteria
- Patients with atherosclerosis or calcific aortic stenosis with and without diabetes older than 18 years of either sex;
- Patients without atherosclerosis undergoing surgical procedure for endocarditis;
- Patients who will have signed informed consent
Exclusion criteria
- Patients for whom biological material cannot be recovered for study purposes;
- Patients who refuse to participate in the study
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
Italy · 1 center
- Irccs Synlab Sdn — Naples
Identifiers
NCT: NCT06337227 · 2/22